Mode
Text Size
Log in / Sign up
N/A N=121 Randomized Double-blind Treatment

A Clinical Trial of a Gamified Attention Bias Modification Training in Anxious Youth

Anxiety Disorders

Enrolled (actual)
121
Serious AEs
3.3%
Results posted
Apr 2024
Primary outcome: Primary: Pediatric Anxiety Rating Scale — 13.596491; 14.557377; 11.50; 12.206897 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Attention Bias Modification Training (Behavioral); Placebo Attention Bias Modification Training (Behavioral)
Age
Pediatric · 8+ yrs
Sex
All
Sponsor
National Institutes of Health Clinical Center (CC)
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Pediatric Anxiety Rating Scale
13.596491; 14.557377; 11.50; 12.206897; 9.666667; 9.890909
PRIMARY
Clinical Global Impression of Improvement Scale
11; 16; 39; 41
SECONDARY
Children's Global Assessment Scale
54.38596; 54.38596; 61.03704; 59.75000; 65.58182; 67.42105
SECONDARY
Screen for Child Anxiety Related Disorders
30.08051; 30.28443; 26.29412; 28.40000; 24.49434; 25.71429
SECONDARY
State-Trait Anxiety Inventory for Children
39.58929; 38.64407; 38.94340; 38.35484; 36.92857; 36.55357
SECONDARY
Self-Efficacy Questionnaire
69.65; 77.61538; 71.76364; 75.21429; 77.57143; 78.07407

Summary

Background: Attention bias modification training (ABMT) and cognitive behavioral therapy (CBT) likely target different aspects of aberrant threat responses in anxiety disorders and may be combined to maximize therapeutic benefit. However, studies investigating the effect of ABMT in the context of CBT have yielded mixed results. Objective: The primary goal of this project is to utilize an enhanced ABMT to target attentional bias towards threat, in addition to classic CBT for anxiety disorders in youth, to determine the efficacy of ABMT in the context of CBT. Study Population: 121 youth (8-17 years old) with a primary anxiety disorder diagnosis Methods: In this sub-study, * Participants will receive open CBT treatment. * Open CBT treatment will be augmented with computer-based attention retraining, delivered in a randomized-controlled design, with random assignment to either active or placebo attention-training regimens. * This enhanced ABMT integrates a modified dot-probe task used in previous studies, where a target is always presented at the previous location of the neutral and not the simultaneously presented threatening stimulus, with a visual search, where the targets are always presented distally of threatening distractors. * These two training elements (modified dot-probe and visual search) will be embedded in an engaging game to foster motivation and adherence. Outcome: Symptom improvement will be compared between the two study arms.

Eligibility Criteria

INCLUSION CRITERIA

-ALL JUVENILE SUBJECTS WITH AN ANXIETY DISORDER:

  • Diagnosis: Current Diagnosis of Social Phobia, Separation Anxiety, Generalized Anxiety Disorder, or Panic Disorder (Based on K-SADS (juveniles))
  • Symptom Severity: Clinically significant, ongoing anxiety symptoms
  • Clinical Impairment: Clinically significant, ongoing distress or impairment from anxiety
  • Age: 8 - 17 (subjects who consent as 17- year-olds but turn 18 during the course of the study will be eligible to complete all procedures completed by other subjects who consent as 17- year- old but do not turn 18).
  • Consent: can give consent/assent (Parents will provide consent; minors will provide assent)
  • IQ: all subjects will have intelligence quotient (IQ) > 70 (Assessment relies on WASI)
  • Language: all subjects will speak English

EXCLUSION CRITERIA

  • Any serious medical condition or condition that interferes with participation
  • Pregnancy
  • Current use of any psychoactive substance; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy.
  • Current diagnoses Tourette's Disorder, obsessive compulsive disorder (OCD), post-traumatic distress disorder, conduct disorder
  • Past or current history of mania, psychosis, or severe pervasive developmental disorder
  • Recent use of an selective serotonin reuptake inhibitor (SSRI); all subjects must have been free of any SSRI-use for at least one month (fluoxetine six months) and must not have been treated with an SSRI for their current depressive episode.
  • National Institute of Mental Health (NIMH) employees and staff and their immediate family members will be excluded from the study per NIMH policy
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03283930). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search